DS
KLRS

David Shaw’s Kalaris Therapeutics KLRS Stock Holding History

David Shaw’s Portfolio KLRS Stock Details KLRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-12,890
Closed -$240K – 4983
2024
Q3 		$240K Sell
12,890
-7,788
-38% -$136K ﹤0.01% 4081
2024
Q2 		$344K Sell
20,678
-17,142
-45% -$303K ﹤0.01% 3822
2024
Q1 		$657K Buy
37,820
+26,836
+244% +$438K ﹤0.01% 3347
2023
Q4 		$172K Buy
+10,984
New +$433K ﹤0.01% 3908
2021
Q2 		– Sell
-2,681
Closed -$1.44M – 5070
2021
Q1 		$1.44M Buy
+2,681
New +$2.25M ﹤0.01% 2833

Other funds holding KLRS

GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

David Shaw's KLRS Position: Q4 2024 in Review

David Shaw sold out of Kalaris Therapeutics (KLRS) in Q4 2024, closing a stake of 12,890 shares — an estimated $240K sold.

David Shaw first reported a position in KLRS in Q1 2021 and held it in 5 quarters. The position peaked at $1.44M in Q1 2021. 52 funds tracked by Wall St. Rank hold KLRS as of Q4 2024.

  • David Shaw reported no remaining Kalaris Therapeutics position as of Q4 2024 after selling out during the quarter.
  • David Shaw sold 12,890 Kalaris Therapeutics shares in Q4 2024, an estimated $240K.
  • David Shaw first reported a position in Kalaris Therapeutics in Q1 2021 and held it in 5 quarters.
  • David Shaw's Kalaris Therapeutics position peaked at $1.44M in Q1 2021.
  • 52 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q4 2024.

Based on D.E. Shaw & Co's 13F filing for Q4 2024, filed 14 Feb 2025.